Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jae Keith Joung
Dana Farber Cancer Inst, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Editas Medicine
Payment for services (e.g., consulting fees, honoraria, paid authorship)
The Partners HealthCare Office for Interactions with Industry (OII) Financial Interest Review Panel evaluated Dr. Joung’s financial interest in Editas Medicine. Editas is developing genome editing technology. This project aims to use CRISPR-Cas technology, to which Editas has licenses for use in therapeutics. It is possible that the project could generate results or IP that could be of interest to the company. The Panel determined that, given Dr. Joung’s role as PI on the grant and the potential that the interests of the company could overlap with the aims of some of the research projects supported by this grant, the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
To clarify, the Editas Medicine public equity value is between (b)(4); and the payment for services was for consulting.
Identifying causal variants and genes underlying breast cancer risk loci
To date, most genetic risk factors for complex traits are located outside of known genes. This proposal focuses on developing strategies for identifying the actual causal variants underlying breast cancer. Employing these strategies will lead to a more profound understanding of the genetic mechanisms that drive breast cancer.
Filed on January 18, 2017.
Tell us what you know about Jae Keith Joung's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Jae Keith Joung”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jae Keith Joung | Massachusetts General Hospital | Conflict of Interest | Beam Therapeutics | Value cannot be readily determined |
| Jae Keith Joung | Massachusetts General Hospital | Conflict of Interest | Editas Medicine | >$600,000 |
| Jae Keith Joung | Dana Farber Cancer Inst | Conflict of Interest | Pairwise Plants | Value cannot be readily determined |
| Jae Keith Joung | Massachusetts General Hospital | Conflict of Interest | Editas Medicine | $10,000 - $19,999 |
| Jae Keith Joung | Massachusetts General Hospital | Conflict of Interest | Transposagen Biopharmaceuticals | Value cannot be readily determined |
| Jae Keith Joung | Dana Farber Cancer Inst | Conflict of Interest | Hera Testing Laboratories | Value cannot be readily determined |
| Jae Keith Joung | Massachusetts General Hospital | Conflict of Interest | Beacon Genomics | Value cannot be readily determined |
| Jae Keith Joung | Massachusetts General Hospital | Conflict of Interest | Beam Therapeutics | Value cannot be readily determined |
| Jae Keith Joung | Dana Farber Cancer Inst | Conflict of Interest | Beam Therapeutics | Value cannot be readily determined |
| Jae Keith Joung | Massachusetts General Hospital | Conflict of Interest | Poseida Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.